BEAM News and Press, Beam Therapeutics Inc. From 11/07/22

Beam Therapeutics ( NASDAQ: BEAM ), a biotech focused on genetic medicines, announced Monday that the company will not file an investigational new drug (IND) for base editing candidate BEAM-102 targeting sickle cell disease in 2022. The shares dropped ~5% in reaction. Th...

Beam Therapeutics press release ( NASDAQ: BEAM ): Q3 GAAP EPS of -$1.56 misses by $0.26 . Revenue of $15.79M (+1977.6% Y/Y) beats by $8.64M . Cash, cash equivalents and marketable securities were $1.1 billion as of September 30, 2022, as compared to $965.6 mill...

Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alph...

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new data supporting the advancement of its Engineered Stem Cell Antibody Paired Evasion (E...

Summary Prime Medicine's technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Beam Therapeutics partnership in sickle cell disease and the experienced management add confidence in the Prime Editing technology. The key pipeline programs could have a peak reve...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

Summary ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. While the larger names in the portfolio do appear to belong, the bulk of the fund is in up-and-coming names, pre-profit, that feel like acquisition i...

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data demonstrating the potential of the company’s multiplex base editin...

Summary Today, we put mid-cap biotech concern Beam Therapeutics Inc. in the spotlight for the first time. Beam Therapeutics is advancing its pipeline on a wide front and the stock has had a nice ride over the past few months. However, most of Beam's candidates are very early s...